Ticagrelor

Known as: (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
010020030019992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed a significant… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
AIMS patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Lars Wallentin, M.D., Ph.D., Richard C. Becker, M.D., Andrzej Budaj, M.D., Ph.D., Christopher P. Cannon, M.D., Håkan Emanuelsson… (More)
  • table 1
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Ticagrelor is the first reversibly binding oral P2Y(12) receptor antagonist. This is the first study to compare the… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS). Current therapies, however, have… (More)
  • table I
  • table III
  • table IV
Is this relevant?